p53 Silenced Endothelial Progenitor Cells for Diabetic Vascular Repair

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Diabetic patients often experience vascular complications due to high glucose levels, which lead to apoptosis of endothelial progenitor cells (EPCs), reducing their ability to differentiate into mature endothelial cells and form new vessels, thereby exacerbating peripheral vascular disease and increasing the risk of amputation.

Innovation Solution

Genetically modifying EPCs to transiently and temporarily reduce p53 expression using siRNA or shRNA, allowing them to survive and differentiate into mature endothelial cells, thereby enhancing their resistance to high glucose conditions and promoting collateral circulation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If EPCs are exposed to high glucose conditions in diabetic patients, then vascular complications worsen due to apoptosis, but reducing p53 expression improves cell survival and differentiation

Engineering Contradiction:

ImproveEPC survival rateVSAvoidhigh glucose-induced apoptosis

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the expression level parameter of p53 gene in EPCs through genetic modification (siRNA or shRNA), reducing p53 expression to alter the cells' response to high glucose conditions. This parameter change transforms EPCs from being susceptible to high glucose-induced apoptosis into having improved survival and differentiation capacity under diabetic conditions.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If p53 expression is reduced in EPCs, then cell survival and differentiation improve, but transient silencing is required to maintain safety

Engineering Contradiction:

ImproveEPC differentiation capacityVSAvoidp53 silencing duration

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent employs transient p53 silencing using siRNA or shRNA that temporarily reduces p53 expression during the critical differentiation period of EPCs. This periodic or transient action allows the cells to survive and differentiate under high glucose conditions without permanent genetic modification, balancing therapeutic benefit with safety by restoring normal p53 function after differentiation is complete.

Inventive Principle:

Principle #19Periodic action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The modified EPCs improve survival and differentiation into mature endothelial cells, increasing capillary formation and reducing the risk of amputation by enhancing collateral circulation in diabetic patients, thus addressing the vascular complications associated with diabetes.

Implementation Method 1

p53 expression may be reduced through the use of p53 specific siRNA or shRNA

Methodology Applied

Scientific EffectRNA interference:

Data Source

PatentUS10016458B2p53 silenced endothelial progenitor cells for diabetes

Publication Date: 2018.07.10 BAYSTATE HEALTH

AI summary

The invention provides, inter alia, methods for treating vascular deficiencies, including those in diabetic subjects, by transplanting endothelial progenitor cells with transiently reduced p53 expression.